S161
Brachytherapy - Urology
ESTRO 2026
results. Grade 3 ED frequently occurs, even in the advent of focal SPBT. Keywords: Salvage prostate BT, Adverse events,
administered in the afternoon and again, the following morning and afternoon, with an interval of at least six hours. The prescribed dose was 3 x 10 Gy on the CTV.Patients were regularly followed up, and AE related to the late GU and GI AE were prospectively scored according to the CTCAE v4 scoring.The incidence of late grade ≥ 2 GU and GI AE was calculated by the Kaplan-Meier method with the 95%CIs. As a secondary endpoint, grade 3 erectile dysfunction (ED) was calculated in the same manner. Late AE was defined as occuring six months after treatment.The late grade 2 GU and GI AE was 35% and 3%, respectively, in a systematic review [1]. The results of our study were compared with the figures of the systematic review. The Z-statistics were used with a one-sided significance level of 5%.The results of late grade 3 ED are reported for patients with grade ≤ 2 ED at baseline. Results: The 3-year late grade ≥ 2 GU and GI AE rate was 47.4% (95%CI 24.0-67.7; P=0.147) and 2.6% (95%CI 0.2-11.8; P=0.43), respectively (Figure1). Two patients had a grade 3 GU adverse event, and one patient had a grade 3 GI adverse event.
Fractionation References: [1]
Shen B, Liu J, Wu D Guo J. Evaluation of the safety and efficacy of high-dose rate brachytherapy for radiorecurrent prostate cancer: a systematic review and meta-analysis. Strahlenther Onkol 2024;200:655- 670. Proffered Paper 1382 Long-Term Survival and Toxicity Outcomes in Over 1,200 Men Aged ≤60 Years Treated with LDR Brachytherapy William Hayhurst 1 , Santiago Uribe 2 , Jennifer Uribe 2 , Claire Deering 2 , Suzanne Langley 2 , Donna Higgins 2 , Sheel Mehta 1 , Sara Khaksar 1 , Christos Mikropoulos 1 , Sophie Otter 1 , Agnieszka Michael 1 , Carla Perna 1 , Stephen Langley 2 1 Oncology, Royal Surrey County Hospital, Guildford, United Kingdom. 2 Brachytherapy, Royal Surrey County Hospital, Guildford, United Kingdom Purpose/Objective: The incidence of prostate cancer in young men ( ≤ 60 years old) is increasing (1). Long-term data on survival and treatment-related effects is key to guide treatment options in these patients with long life expectancies. LDR brachytherapy offers an effective, targeted, high dose treatment, with a subsequent low toxicity profile (2). We present the long term outcomes of men aged ≤ 60 years at implantation. Material/Methods: Patients were stratified into low, intermediate and high-risk (LR, IR, HR) groups as per NICE guidance (3). LDR implants were carried out using the 4D brachytherapy technique, with stranded and loose Iodine-125 seeds (4). LR and IR patients with Gleason 3+4 pattern and <50% core involvement underwent LDR implant (145Gy) as a monotherapy. 6 months of Androgen deprivation therapy (ADT) was added for IR patients with Gleason 4+3 disease or >50% core involvement. Tri-modal treatment (ADT, EBRT and LDR brachytherapy [110Gy]) was offered to HR patients. Urinary, erectile potency, and bowel toxicity data was captured prospectively using the IPSS, IIEF-5S, and EORTC QLQ - PR25 (bowel component) instruments. Treatment relapse was defined as biochemical recurrence (nadir +2ng/mL), or clinical and radiological failure. Results: 1204 patients were treated from 1999 to 2022 with a median follow up of 12.5 years. The median age at implant was 57 years. Dosimetry analysis showed a
The 3-year late grade 3 ED was 91% (95%CI 50.3-98.7). Conclusion: Focal SPBT with three fractions of 10 Gy in one implantation did not result in a higher incidence of late GU and GI severe AE. This treatment regimen can be considered safe. A limitation of the study is the small number of patients, which has resulted in relatively wide CIs and less precise estimation of the
Made with FlippingBook - Share PDF online